Synonym
Dobutamine phosphate, (S)-;
IUPAC/Chemical Name
(S)-4-(2-((4-(4-hydroxyphenyl)butan-2-yl)amino)ethyl)benzene-1,2-diol phosphate
InChi Key
JJDDIKDNBCHINM-ZOWNYOTGSA-N
InChi Code
InChI=1S/C18H23NO3.H3O4P/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15;1-5(2,3)4/h4-9,12-13,19-22H,2-3,10-11H2,1H3;(H3,1,2,3,4)/t13-;/m0./s1
SMILES Code
OP(O)(O)=O.C[C@@H](CCC1=CC=C(O)C=C1)NCCC2=CC(O)=C(O)C=C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
399.38
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci. 1987 Oct;294(4):244-8. doi: 10.1097/00000441-198710000-00005. PMID: 3310640.
2: Dubin A, Lattanzio B, Gatti L. The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients. Rev Bras Ter Intensiva. 2017 Oct-Dec;29(4):490-498. doi: 10.5935/0103-507X.20170068. PMID: 29340539; PMCID: PMC5764562.
3: Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196-202. doi: 10.1016/s0140-6736(02)09455-2. PMID: 12133653.
4: O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 Jul;138(1 Pt 1):78-86. doi: 10.1016/s0002-8703(99)70250-4. PMID: 10385768.
5: Mahoney L, Shah G, Crook D, Rojas-Anaya H, Rabe H. A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates. Pediatr Cardiol. 2016 Jan;37(1):14-23. doi: 10.1007/s00246-015-1263-9. Epub 2015 Sep 7. Erratum in: Pediatr Cardiol. 2016 Dec 1;: PMID: 26346024.
6: Mielgo V, Valls i Soler A, Rey-Santano C. Dobutamine in paediatric population: a systematic review in juvenile animal models. PLoS One. 2014 Apr 22;9(4):e95644. doi: 10.1371/journal.pone.0095644. PMID: 24755688; PMCID: PMC3995779.
7: Al Madfai F, Valah B, Zaidi STR, Wanandy T, Ming LC, Peterson GM, Patel RP. Stability of dobutamine in continuous ambulatory delivery devices. J Clin Pharm Ther. 2018 Aug;43(4):530-535. doi: 10.1111/jcpt.12674. Epub 2018 Mar 2. PMID: 29500838.
8: Madias JE. Pathophysiological insights from dobutamine-induced Takotsubo syndrome. Anatol J Cardiol. 2018 Aug;20(2):134. doi: 10.14744/AnatolJCardiol.2018.50708. PMID: 30088490; PMCID: PMC6237951.
9: Wislicki L. [Dobutamine]. Harefuah. 1979 Dec;97(11-12):312-3. Hebrew. PMID: 16296120.
10: Kittleson MD. Dobutamine. J Am Vet Med Assoc. 1980 Oct 1;177(7):642-3. PMID: 7440359.
-1008.jpg "Dobutamine phosphate, (S)-")
